CIMG Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CIMG Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Sep 30, 2019 | $1.79M | Dec 26, 2019 |
| FY2019 | Sep 30, 2018 | $1.39M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $1.63M | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | $455.5K | Feb 22, 2018 |
| FY2016 | Sep 30, 2015 | $115.0K | Dec 29, 2016 |
| FY2015 | Sep 30, 2014 | $71.8K | Jan 13, 2016 |
| FY2014 | Sep 30, 2013 | $122.2K | Feb 12, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $10.30M | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | $1.93M | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | $1.76M | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | $3.11M | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $1.93M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $1.40M | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | $1.79M | Dec 28, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $125.8K | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | $32.2K | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | ($210.8K) | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | ($110.4K) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | ($80.1K) | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | ($239.0K) | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | $295.1K | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $67.2K | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $309.2K | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | $47.3K | Feb 22, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($4.88M) | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | ($8.97M) | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | ($8.75M) | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | ($11.80M) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | ($18.55M) | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | ($9.48M) | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | ($12.19M) | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | ($3.58M) | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | ($1.78M) | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | ($1.28M) | Feb 22, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($5.20M) | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | ($10.86M) | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | ($8.39M) | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | ($11.40M) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | ($18.00M) | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | ($9.33M) | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | ($12.10M) | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | ($3.62M) | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | ($1.77M) | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | ($1.28M) | Feb 22, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $633 | Dec 23, 2022 |
| FY2022 | Sep 30, 2021 | $1.8K | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $11.4K | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | $1.8K | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $18.2K | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $18.9K | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | $9.4K | Feb 22, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $10.62M | Dec 23, 2022 |
| FY2022 | Sep 30, 2021 | $17.08M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $1.43M | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | $1.04M | Dec 28, 2020 |
| FY2017 | Sep 30, 2017 | $741.6K | Feb 22, 2018 |
| FY2017 | Sep 30, 2016 | $308.6K | Feb 22, 2018 |
| FY2015 | Sep 30, 2015 | $363.8K | Jan 13, 2016 |
| FY2015 | Sep 30, 2014 | $2.93M | Jan 13, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($17.59M) | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | ($9.97M) | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | ($6.38M) | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | ($7.46M) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | ($7.11M) | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | ($4.24M) | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | ($4.40M) | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | ($2.31M) | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | ($1.40M) | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | ($1.15M) | Feb 22, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2024 | $319.8K | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | $31.8K | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | $191.8K | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $115.4K | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $119.8K | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | $1.47M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $550.2K | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $187.0K | Feb 11, 2019 |
| FY2016 | Sep 30, 2016 | ($4.5K) | Dec 29, 2016 |
| FY2016 | Sep 30, 2015 | ($235.6K) | Dec 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $74.18M | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | $5.59M | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | $4.44M | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | $11.71M | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $13.74M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $8.18M | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | $5.25M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $2.98M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $1.25M | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | $522.4K | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $27.65M | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | $6.24M | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | $2.77M | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | $1.97M | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $1.53M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | $1.79M | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | $1.14M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $570.4K | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $493.6K | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | $945.0K | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $45.74M | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | ($650.7K) | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | $1.67M | Jul 30, 2025 |
| FY2024 | Sep 30, 2022 | $9.74M | Jul 30, 2025 |
| FY2023 | Sep 30, 2021 | $12.21M | Jan 16, 2024 |
| FY2022 | Sep 30, 2020 | $6.39M | Dec 23, 2022 |
| FY2020 | Sep 30, 2019 | $4.01M | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | $2.32M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $667.8K | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | ($422.7K) | Feb 22, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2020 | $17.1K | Dec 28, 2020 |
| FY2019 | Sep 30, 2019 | $0 | Dec 26, 2019 |
| FY2019 | Sep 30, 2018 | $17.1K | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $17.1K | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | $0 | Feb 22, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($87.23M) | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | ($82.34M) | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | ($73.37M) | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | ($64.62M) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | ($52.82M) | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | ($34.27M) | Dec 22, 2021 |
| FY2020 | Sep 30, 2019 | ($24.80M) | Dec 28, 2020 |
| FY2019 | Sep 30, 2018 | ($12.61M) | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | ($9.03M) | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | ($7.26M) | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $137.3K | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | $464.2K | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | $982.9K | Jul 30, 2025 |
| FY2019 | Sep 30, 2019 | $1.33M | Dec 26, 2019 |
| FY2019 | Sep 30, 2018 | $1.81M | Dec 26, 2019 |
| FY2019 | Sep 30, 2017 | $347.3K | Dec 26, 2019 |
| FY2018 | Sep 30, 2016 | $40.6K | Feb 11, 2019 |
| FY2017 | Sep 30, 2015 | $107.7K | Feb 22, 2018 |
| FY2016 | Sep 30, 2014 | $238.2K | Dec 29, 2016 |
| FY2015 | Sep 30, 2013 | $1.11M | Jan 13, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $56.3K | Dec 22, 2021 |
| FY2020 | Sep 30, 2020 | $112.9K | Dec 28, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (2) | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | (83) | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | (11) | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | (21) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | (1) | Dec 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (2) | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | (83) | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | (11) | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | (21) | Jan 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 9.83M | Feb 13, 2026 |
| FY2025 | Sep 30, 2024 | 248,912 | Feb 13, 2026 |
| FY2024 | Sep 30, 2023 | 748,644 | Jul 30, 2025 |
| FY2023 | Sep 30, 2022 | 676,229 | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | 17.82M | Dec 23, 2022 |
| FY2021 | Sep 30, 2020 | 14.57M | Dec 22, 2021 |
| FY2019 | Sep 30, 2019 | 13.62M | Dec 26, 2019 |
| FY2019 | Sep 30, 2018 | 13.19M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | 34.72M | Feb 11, 2019 |
| FY2017 | Sep 30, 2016 | 31.15M | Feb 22, 2018 |